Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma
Trial ID or NCT#
NCT00373347
Status
RECRUITING
Purpose
The purpose of this study is to identify blood markers that have the ability to diagnose liver cancer with improved accuracy, so that it can be used alone or in conjunction with alpha-feto protein (AFP)
Official Title
Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
- - Patients diagnosed with liver cancer based on biopsy or serum AFP level, associated with characteristic hypervascular liver tumors on triphasic spiral CT scan or MRI. - Patients with non-cancer liver conditions such as cirrhosis, adenoma, cholangioma, or nodular hyperplasia. - Patients with hepatitis B or hepatitis C viral infections not associated with liver cancer.
Exclusion Criteria:
- -Patients will be excluded if, upon looking through their medical records, information required for data analysis are missing.
Investigator(s)
Samuel So, MD
Surgical oncologist,
Liver surgeon,
General surgeon
Lui Hac Minh Professor in the School of Medicine
Contact us to find out if this trial is right for you.
Contact
Mei-Sze Chua
650-724-3525
View on ClinicalTrials.gov